Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALIG-CBD: CBD in Virologically Controlled HIV
NCT05306249Phase 2Completed
- Sponsor
- Centre Hospitalier Régional d'Orléans
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in human immunodeficiency virus infection (HIV), sponsored by Centre Hospitalier Régional d'Orléans. Started May 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05306249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306249.